An update on biology, diagnosis and treatment of primary plasma cell leukemia

Pellegrino Musto, Teodora Statuto, Luciana Valvano, Vitina Grieco, Filomena Nozza, Gabriella Vona, Giovanni Battista Bochicchio, Francesco La Rocca, Fiorella D’Auria

Research output: Contribution to journalReview articlepeer-review


Introduction: Primary plasma cell leukemia (PPCL) is one of the most aggressive hematological malignancies. The prognosis of PPCL patients remains poor, although some improvements have been made in recent years. Areas covered: In this review recent clinical and biological advances in PPCL are reported. Some recommendations for the practical management of these patients are provided, with a particular focus on the role of novel agents and transplant procedures. A brief description of the currently ongoing clinical trials with new drugs is also enclosed. Expert opinion: PPCL still represents a difficult challenge for all hematologists. Here the authors provide a personal view on how the current, generally unsatisfactory results in this neoplastic disorder could be improved. In particular, dedicated studies exploring alternative therapies are necessary and eagerly awaited. Such studies should possibly be based on new biological information that could be of help in identifying novel genetic biomarkers for risk stratification and new actionable molecular targets.

Original languageEnglish
Pages (from-to)245-253
Number of pages9
JournalExpert Review of Hematology
Issue number4
Publication statusPublished - Apr 3 2019


  • flow cytometry
  • Genomics
  • multiple myeloma
  • novel agents
  • plasma cell leukemia
  • prognostic factors
  • stem cell transplantation

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'An update on biology, diagnosis and treatment of primary plasma cell leukemia'. Together they form a unique fingerprint.

Cite this